Amlexanox Inhibits Cerebral Ischemia-Induced Delayed Astrocytic High-Mobility Group Box 1 Release and Subsequent Brain Damage

Sebok Kumar Halder and Hiroshi Ueda

Department of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Received September 25, 2017; accepted January 10, 2018

ABSTRACT

High-mobility group box 1 (HMGB1) is increased in the cerebrospinal fluid (CSF) and serum during the early and late phases of brain ischemia and is known to contribute to brain damage. However, detailed characterization underlying cell type-specific HMGB1 release and pathophysiological roles of extracellularly released HMGB1 in ischemic brain remain unclear. Here, we examined cell type-specific HMGB1 release and the therapeutic potential of amlexanox, an inhibitor of nonclassical release, and of an anti-HMGB1 antibody against ischemic brain damage. HMGB1 depletion from neuronal nuclei was observed within 3 hours after transient middle cerebral artery occlusion (tMCAO), whereas the intracerebroventricular (i.c.v.) pretreatment with amlexanox blocked HMGB1 release from neurons, resulting in HMGB1 redistribution in the nuclei and cytoplasm. HMGB1 was selectively released from astrocytes 27 hours after tMCAO and this HMGB1 release was blocked by late treatment with amlexanox (i.c.v.) 24 hours after tMCAO. Proximity extension assay revealed that the HMGB1 level was elevated in the CSF at 3 and 27 hours after tMCAO. This late treatment with amlexanox significantly protected the brain from ischemic damage, but its pretreatment 30 minutes before tMCAO failed to show any protection. The late treatment (i.c.v.) with anti-HMGB1 antibody 24 hours after tMCAO also ameliorated ischemic brain damage 48 hours after tMCAO. Thus, the inhibition of brain damage by late treatment with amlexanox or anti-HMGB1 antibody indicates that late HMGB1 release plays a role in the maintenance of stroke-induced brain damage, and the inhibition of this release would be a novel therapeutic target for protection of ischemic brain damage.

Introduction

High-mobility group box 1 (HMGB1), a nuclear protein, is ubiquitously expressed throughout mammalian tissues including the brain. It is involved in diverse intracellular functions, such as nucleosome sliding, recombination, and regulation of transcription (Lange et al., 2008; Stros, 2010; Harris et al., 2012). In addition to its intracellular roles, extracellular functions of HMGB1 in cell proliferation, migration, differentiation, tissue regeneration, and pathogenesis of inflammation and diseases have also been reported (Erlandsson Harris and Andersson, 2004; Palumbo et al., 2009; Andersson and Tracey, 2011; Tang et al., 2011). Previous studies showed that HMGB1 is released either actively from monocytes and macrophages or passively from injured/damaged cells following ischemic/necrotic stress (Lotze and Tracey, 2005; Tang et al., 2011), and this extracellularly released HMGB1 functions as a cytotoxic mediator through activation of receptor for advanced glycation end products (AGEs) and Toll-like receptors (TLR)-2 and -4 (Yu et al., 2006; Klune et al., 2008; Muhammad et al., 2008). Thus, HMGB1 is known as a representative member of damage-associated molecular patterns (DAMPs)’ family molecules.

In the brain, HMGB1 is rapidly released from neurons or astrocytes by various stresses, including ischemia and immunological stress, whereas ischemia-induced HMGB1 release from microglia occurs as late as 1 week after the stress (Kim et al., 2006; Hayakawa et al., 2008). Thus, released HMGB1 is known to cause a neurodegeneration, and the neutralization of extracellular HMGB1 prevents the progression of ischemic brain damage (Liu et al., 2007; Yang et al., 2010). For an improved understanding of strategic treatments using small molecules against ischemic brain damage, it is important to examine which cell types and what time points are responsible for the HMGB1 release in terms of brain damage.

One strategy to suppress the inflammatory actions of DAMPs could be the use of an inhibitor of DAMPs release, though the manner of DAMPs release is considered to be performed in an unidentified nonclassical release. Previous studies reported that amlexanox (2-amino-7-isopropyl-5-oxo-5H-[1]benzopyrano[2,3-b]...
pyridine-3-carboxylic acid), an antiallergy drug, inhibits the stress-induced nonclassical release of representative DAMPs molecule interleukin-1α (IL-1α) (Okada et al., 2003; Mohan and Yu, 2011) and neurotrophic or neuroprotective DAMPs molecule, such as fibroblast growth factor-1 (FGF-1) (Mota Carreira et al., 1998; Landriscina et al., 2000) and prothymosin alpha (ProTα) (Fujita and Ueda, 2007; Fujita et al., 2009; Matsunaga and Ueda, 2010; Halder et al., 2012, 2015; Ueda et al., 2012).

In the present study, we examined ischemia-induced HMGB1 release from the tempo-spatial point of view, in an attempt to evaluate the effects of amlexanox on HMGB1 release and brain damage.

Materials and Methods

Animals. Male C57BL/6j mice (6-week-old, 20–24 g body weight) were purchased from Tagawa Experimental Animals (Nagasaki, Japan). Mice were housed in a room maintained at a temperature of 21 ± 2°C and relative humidity of 55 ± 5% with a 12-hour light/dark cycle. Mice had free access to both standard laboratory diet and tap water. All procedures were approved (protocol number: 1104190914) by Nagasaki University Animal Care Committee (Nagasaki, Japan).

Amlexanox and Anti-HMGB1 Antibody Treatments. Amlexanox was purchased from Takeda Pharmaceutical Company Ltd. (Osaka, Japan) and dissolved in autoclaved phosphate-buffered saline (PBS). Anti-HMGB1 antibody (rabbit polyclonal) was purchased from Abcam (Cambridge, MA) and diluted in autoclaved PBS. Intracerebroventricular (i.c.v.) injection takes advantage of the animal ventricular system that bathes the whole brain, allowing widespread distribution of the injected molecules. In i.c.v. injection, a small dose of injected molecules is sufficient to reach the molecular target within brain tissue. In contrast, systemically administered molecules may fail to reach therapeutic levels in the brain at different time points after cerebral ischemia, owing to their degradation in blood. Considering these issues, we performed i.c.v. injection using a Hamilton syringe to get a direct effect of amlexanox or anti-HMGB1 antibody on the brain tissue as well as to minimize any other peripheral targets. The following mice groups were used throughout the study: Mice received amlexanox (10 μg/5 μl, i.c.v.) 30 minutes before 1-hour transient middle cerebral artery occlusion (tMCAO) (n = 6) or 15-minute tMCAO (n = 6). Mice received amlexanox (10 μg/5 μl, i.c.v.) 24 hours after 1-hour tMCAO (n = 6) or 30-minute tMCAO (n = 9). Mice received amlexanox (10 μg/5 μl, i.c.v.) 48 hours after 30-minute tMCAO (n = 4). Amlexanox was also injected (10 μg/5 μl, i.c.v.) in nonischemic mice (n = 6). Mice received anti-HMGB1 antibody (1 or 3 μg/5 μl, i.c.v.) 24 hours after 30-minute tMCAO (n = 3) or 1-hour tMCAO (n = 6). Ischemic (tMCAO) vehicles were prepared by PBS injection (i.c.v.). Mice receiving neither surgery (tMCAO) nor injection were referred to as the untreated group, which was used as control to compare with ischemic vehicle.

Middle Cerebral Artery Occlusion Model. tMCAO was performed according to a previously described standard protocol (Egashira et al., 2004). Briefly, mice were first anesthetized with 2% isoflurane (Mylan, Tokyo, Japan) and during the period of occlusion (Egashira et al., 2004). Briefly, mice were first anesthetized with 2% isoflurane (Mylan, Tokyo, Japan) and during the period of occlusion (Egashira et al., 2004). Briefly, mice were first anesthetized with 2% isoflurane (Mylan, Tokyo, Japan) and during the period of occlusion.
Amlexanox-treated tMCAO brain (0.05 M Tris-HCl buffer (pH 7.6), 1% cobalt chloride (CoCl2), and 1% nickel sulfate (NiSO4) solution (Sigma-Aldrich, St. Louis, MO). The sections were dehydrated through a series of ethanol solutions, fixed in xylene, and cover-slipped with Thermo Scientific PermaFluor (Thermo Fisher Scientific). Immunoreactivity of HMGB1-positive cells (black reaction products) was analyzed using a BZ-8000 microscope with BZ image measurement software (KEYENCE, Osaka, Japan). For fluorescence immunostaining, the brain sections were washed with K+-free PBS and sequentially incubated with 50 and 100% methanol. The sections were treated with blocking buffer (2 or 3% BSA in 0.1% PBST) and incubated overnight at 4°C with following primary antibodies: anti-NeuN (1:100; mouse monoclonal IgG; Chemicon, Temecula, CA); anti-GFAP (1:400; mouse monoclonal IgG; Chemicon); and rabbit polyclonal (1:500; Dako, Glostrup, Denmark), anti-Iba-1 (1:500; goat polyclonal IgG; Abcam), and anti-HMGB1 IgG (1:100; rabbit polyclonal IgG; Abcam). The sections were then incubated with Alexa Fluor 594-conjugated anti-rabbit IgG, Alexa Fluor 488-conjugated anti-mouse IgG, Alexa Fluor 488-conjugated anti-goat IgG (1:300; Molecular Probes, Eugene, OR). The nuclei were visualized with Hoechst 33342 (1:10,000; Molecular Probes). The sections were washed with PBS and cover-slipped with Thermo Scientific PermaFluor (Thermo Fisher Scientific). Images were collected using a BZ-8000 microscope with BZ image measurement software (KEYENCE).

Cell Counting. Measurement of HMGB1-positive cells in the brain was carried out according to a previously described protocol (Halder et al., 2012). Briefly, the counting of HMGB1-positive cells in the coronal brain sections was performed in bright-field images using a BZ-8000 microscope with BZ image measurement software (KEYENCE). Cell-type-specific markers with clearly visible nuclei using Hoechst 33342 staining were used to detect HMGB1 signals in neuronal nuclei (NeuN)-positive neurons, ionized calcium-binding adapter molecule-1 (Iba1)-positive microglia, and glial fibrillary acidic protein (GFAP)-positive astrocytes. The number of HMGB1-positive neurons, astrocytes and microglia were stereologically counted (bregma 0.68–2.08) in the square fields (approximately 250 × 250 μm) of untreated brain (n = 3), vehicle-treated tMCAO brain (n = 3), and amlexanox-treated tMCAO brain (n = 3) and were normalized to the untreated brain (n = 3). The quantification was expressed as the average percentage of the total number of cell-type-specific HMGB1-positive cells in the three coronal brain sections per mouse.

Triphenyltetrazolium Chloride Staining. To perform 2,3,5-triphenyltetrazolium chloride (TTC) staining, the brain was quickly removed and sectioned coronally to 1-mm thickness. TTC (Sigma-Aldrich) was dissolved in 0.9% physiologic saline (Otsuka Pharmaceutical Co. Inc., Tokyo, Japan). Brain slices were washed with PBS and then incubated with 2% TTC in the dark for 15–20 minutes at room temperature (25°C). Brain slices were further incubated with 4% PFA overnight at 4°C. Images of brain slices were obtained by scanner (EPSON GT-9700F) and infarct volume was measured by Image J software (NIH, Bethesda, MD).

Behavioral Assessments. According to a previously described protocol (Wang et al., 2015; Maeda et al., 2016), clinical (neurologic) scores were measured after tMCAO using a six-point (0–5) scale: 0 = no observable deficits; 1 = failure to extend the forepaw fully; 2 = circling to the left; 3 = falling to the left side; 4 = no spontaneous movement; 5 = death. In this study, 0.5 points were added to each score when the motor dysfunction was severe for scores between 1 and 4.

Statistical Analysis. Data are means ± S.E.M. Two independent groups were compared using Student’s t test. Multiple groups were compared using Dunnett’s multiple comparison tests after one-way analysis of variance (ANOVA). P < 0.05 was considered significant.

Results

Ischemia-Induced Elevation of HMGB1 Level in the CSF. To confirm whether HMGB1 is released from brain after cerebral ischemia, CSF was collected from the cisterna magna at 3 and 27 hours after the 1-hour tMCAO. As shown in Fig. 1A, the detection limit of HMGB1 level in the PEA was below 2 pM. The PEA study revealed that the HMGB1 levels at 3 and 27 hours after tMCAO were significantly higher than in the untreated mice (Fig. 1B).

Amlexanox Reverses Ischemia-Induced Depletion of HMGB1 in the Brain. The HMGB1 immunoreactivities by DAB staining were widely distributed in nuclei in the brain cells of cerebral cortex, striatum, and hippocampus (Fig. 2, A–C). The tMCAO treatment of 1 hour depleted the HMGB1

Fig. 1. HMGB1 is elevated in the cerebrospinal fluid following cerebral ischemia. (A) Calibration curve for HMGB1. Proximity extension assay (PEA) was performed to generate the calibration curve using 70, 100, and 300 pM, and 1 and 3 nM Strep-tagged mouse HMGB1 and a zero buffer. Average cycle threshold (Ct) values are plotted on the y-axis and concentrations of HMGB1 on the x-axis. (B) Cerebrospinal fluid (CSF) was withdrawn from the cisterna magna of mouse brain at 0 (untreated), 3, and 27 hours after 1-hour tMCAO, and HMGB1 level was measured using PEA. HMGB1 level in the CSF was measured by converting the Ct values into the concentrations. Data are means ± S.E.M. *P < 0.05 vs. untreated mice, **P < 0.01 vs. untreated mice; n = 3 in each group.
immunoreactivities from most cells in these three regions in the brain at 3 hours after tMCAO, though some cells still retained an HMGB1 signal. Although the cell type showing HMGB1 release 3 hours after tMCAO was not determinable by this method, it appears it was astrocytes in the image in Fig. 2C, which shows a complete depletion of HMGB1 in the hippocampal pyramidal neuronal layer of cornu ammonis (CA1). The decreased HMGB1 levels were largely recovered at 27 hours after tMCAO (Fig. 2, A–C). The pretreatment with amlexanox (10 μg/5 μl, i.c.v.) 30 minutes prior to tMCAO reversed the decrease in neuronal nuclear HMGB1 levels at 3 hours, though there was no change in the HMGB1 levels at 27 hours (Fig. 2, A–C).

Amlexanox-Reversible Blockade of Rapid HMGB1 Depletion in Neurons. When the section of cortex was costained with anti-NeuN and anti-HMGB1 antibodies, all neurons were found to contain HMGB1 within their nuclei, as shown in Fig. 3A. The HMGB1 immunoreactivities were completely lost from neurons at 3 hours after 1-hour tMCAO (Fig. 3A). The pretreatment with amlexanox (10 μg/5 μl, i.c.v.) 30 minutes prior to tMCAO also reversed the decrease of HMGB1 levels at 3 hours, but HMGB1 immunoreactivities were found both in the cytosol and nucleus. As seen in Fig. 3A, most of the HMGB1 immunoreactivity was recovered only in the nuclei at 27 hours after tMCAO. The pretreatment with amlexanox did not show any change in the HMGB1 level at 27 hours, but HMGB1 signals were found only in the nucleus. Quantitative analysis evaluating the number of HMGB1-positive neurons also supported the significant amlexanox-reversible HMGB1 release from cortical neurons (Fig. 3B). Similar amlexanox-reversible HMGB1 release from striatal and hippocampal neurons was also observed at 3 hours after MCAO (Fig. 3, C–E).

Late Release of Astroglial HMGB1 Is Blocked by Amlexanox. As shown in the untreated preparation (Fig. 4, A and B), less intensive HMGB1-positive cells appear to be GFAP-positive astrocytes. The tMCAO stress for 1 hour caused a depletion of HMGB1 signals from GFAP-negative cells at 3 hours after tMCAO but not from GFAP-positive astrocytes, where HMGB1 was retained in the nuclei (Fig. 4, B and C). The nuclear HMGB1 signal in astrocytes was still observed at 18 hours after tMCAO but was completely lost at 27 hours after tMCAO (Fig. 4C). When amlexanox (10 μg/5 μl, i.c.v.) was pretreated 30 minutes before or 24 hours after tMCAO, intense HMGB1 signals still remained in the nuclei in astrocytes at 3 or 27 hours, respectively (Fig. 4, B and C). The quantitatively significant decrease in the number of HMGB1-positive astrocytes and its recovery by amlexanox are shown in Fig. 4C. As seen in Fig. 4D, HMGB1 immunoreactivities were recovered only in the nuclei of astrocytes at 48 and 96 hours after tMCAO. The amlexanox treatment 24 hours after tMCAO did not show any change in the HMGB1 levels at 48 and 96 hours, but all HMGB1 signals were observed only in the nuclei of astrocytes (Fig. 4D).

Ischemia-Induced Persistent Expression of HMGB1 in Microglia. As shown in untreated preparations of Fig. 5, A and B, Iba-1-positive microglia residing in the somatosensory cortex of untreated mice have no HMGB1-immunoreactivities. However, cerebral ischemia (1-hour tMCAO) caused an expression of HMGB1 in nuclei of cortical microglia on the ipsilateral side at 3 hours after tMCAO, and the expression became more intense at 27 hours after tMCAO (Fig. 5B). The pretreatment with amlexanox 30 minutes before or 24 hours after tMCAO had no effect on tMCAO-induced HMGB1 expression in the nuclei of microglia at 3 or 27 hours. After a 1-hour tMCAO, intense HMGB1 signals were also observed in preparations of striatum and stratum radiatum (str rad), as shown in Supplemental Fig. 1, A–D.

![Fig. 2. Blockade of cerebral ischemia-induced release of HMGB1 by amlexanox. (A–C) Mice were pretreated with amlexanox (Amx) at a dose of 10 μg/5 μl (i.c.v.) 30 minutes before 1-hour tMCAO and DAB immunostaining using coronal brain sections was performed at 3 hours after tMCAO. Following Amx post-treatment (10 μg/5 μl, i.c.v.) at 24 hours after 1-hour tMCAO, DAB immunostaining was performed at 27 hours after tMCAO. Representative images show immunoreactive HMGB1 in the somatosensory cortex (A), striatum (B), and hippocampus (Hip) (C). Immunoreactive HMGB1 in stratum radiatum (Str rad) in the Hip of untreated mice is indicated by black arrows. Red-colored arrows indicate HMGB1 immunoreactivity at 3 hours after tMCAO. Red-colored arrowheads indicate HMGB1 immunoreactivity in the Str rad at 27 hours after tMCAO. Insets in (A–C) indicate the higher magnification view of immunoreactive HMGB1 in the cortex (A), striatum (B) and cornu ammonis (CA1) of Hip (C) noted by red squares. n = 3 in each group.](image-url)
27 hours, respectively (Fig. 5B). Quantitative analysis revealed that tMCAO increased the number of HMGB1-positive microglia, but amlexanox did not affect the population at 3 and 27 hours (Fig. 5C). Similar negative effects of amlexanox on microglial HMGB1 expression at 48 and 96 hours were observed after the amlexanox treatment at 24 hours after tMCAO (Fig. 5D).

**Pretreatment with Amlexanox Exacerbates the Ischemic Brain Damage.** Following amlexanox pretreatment (10 μg/5 μl, i.c.v.) 30 minutes before lethal cerebral ischemia (1-hour tMCAO), maximum infarct volume was obtained at 24 hours after tMCAO in either vehicle-pretreated or amlexanox-pretreated mice, as shown by TTC staining (Fig. 6, A and B). As it is difficult to evaluate the effect of amlexanox against ischemia-induced brain damage using the 1-hour tMCAO model, we used a mild cerebral ischemia model (15-minute tMCAO) to evaluate the beneficial effects of amlexanox. TTC staining revealed that infarct volume was significantly increased at day 1 (24 hours) after 15-minute tMCAO in amlexanox-pretreated (30 minutes before tMCAO) mice, compared with ischemic vehicle (Fig. 6, C and D). Clinical score was also significantly increased at day 1 (24 hours) after 15-minute tMCAO in amlexanox-pretreated mice, compared with ischemic vehicle (Fig. 6E). However, any changes in behaviors or in the infarct volume were not observed following treatment with amlexanox in nonischemic mice (Fig. 6E).

**Late Treatment with Amlexanox Ameliorates the Ischemic Brain Damage.** As mice show poor survival 4-6 days after 1-hour tMCAO (Halder et al., 2013), we used a 30-minute tMCAO model for behavioral assessments every day for 7 days to evaluate the beneficial effects of amlexanox late treatment. When mice were treated with amlexanox at 24 hours after 30-minute tMCAO, infarct volume was significantly decreased at 48 hours after tMCAO (Fig. 7, A and B). Clinical score was also significantly decreased at day 4 (96 hours) after 30-minute tMCAO in amlexanox post-treated (24 hours after tMCAO) mice, but the clinical score was gradually increased from day 5 and continued to day 7 after tMCAO (Fig. 7C). There was no change in infarct volume and clinical score at 72 hours after 30-minute tMCAO when mice were treated with amlexanox at 48 hours after tMCAO (Fig. 7, D–F).

**Late Treatment with Anti-HMGB1 Antibody Reduces the Ischemic Brain Damage.** To investigate whether ischemia-induced brain damage is inhibited by neutralization of released HMGB1, mice were treated with polyclonal anti-HMGB1 antibody (1 or 3 μg/5 μl, i.c.v.) at 24 hours after 30-minute tMCAO or 1-hour tMCAO. TTC staining revealed that infarct volume was markedly increased 48 hours after mild cerebral ischemia (30-minute tMCAO), whereas post-treatment (24 hours) with 3 μg of anti-HMGB1 antibody (but not 1 μg) significantly reduced the infarct volume at 48 hours after 30-minute tMCAO (Fig. 8, A and B). Post-treatment with anti-HMGB1 antibody (3 μg/5 μl, i.c.v.) at 24 hours after lethal cerebral ischemia (1-hour tMCAO) also significantly reduced infarct volume 48 hours after tMCAO, compared with vehicletreated ischemic mice (Fig. 8, C and D). Moreover, the clinical score was significantly decreased through 7 days after 1-hour...
tMCAO when mice were post-treated with 3 μg anti-HMGB1 antibody (Fig. 8E).

Discussion

The present study includes the following major findings: 1) Pre-treatment with amlexanox 30 minutes before tMCAO-type cerebral ischemia reversibly blocks HMGB1 release from neurons at 3 hours after the ischemic stress, 2) post-treatment with amlexanox 24 hours after cerebral ischemia reversibly blocks HMGB1 release only from astrocytes at 27 hours after ischemia, 3) post-treatment with amlexanox protects the brain from ischemic damage, but as a pretreatment it fails to show any protection, and 4) post-treatment with an anti-HMGB1 antibody 24 hours after cerebral ischemia ameliorates ischemic brain damage.
HMGB1 is released from neurons, some astrocytes, and microglia in response to ischemic stress (Hayakawa et al., 2008; Qiu et al., 2008), but it remains to be determined how the HMGB1 release occurs following cerebral ischemia in terms of time and cell-type specificity, and whether the release has pathophysiological roles in the post-ischemic brain. In the present study, immunohistochemistry showed that HMGB1 was completely released from nuclei of neurons at 3 hours after cerebral ischemia (1-hour tMCAO). On the other hand, HMGB1 was not released from astrocytes in the early phase of cerebral ischemia. It was found that neurons are the principal sources of HMGB1 in the early phase of brain ischemia/injury and this neuron-derived HMGB1 functions as an early upstream cytotoxic factor to cause ischemia-induced brain damage (Qiu et al., 2008).

Fig. 5. Cerebral ischemia-induced expression of HMGB1 in microglia. (A) Mice were pretreated with amlexanox (Amx) at a dose of 10 μg/5 μl (i.c.v.) 30 minutes before 1 hour tMCAO and immunostaining of Iba-1 and HMGB1 (Iba-1, green; HMGB1, red) in the somatosensory cortex using coronal brain sections was performed at 3 hours after tMCAO. Following Amx post-treatment (10 μg/5 μl, i.c.v.) at 24 hours after 1-hour tMCAO, immunostaining of Iba-1 and HMGB1 was performed at 27 hours after tMCAO. Insets indicate higher magnification view of immunoreactive-HMGB1 in Iba-1-positive microglia noted by dotted squares. (B) Triple immunostaining (Iba-1, green; HMGB1, red; Hoechst, blue) show the higher magnification view of HMGB1 localization in microglia at 0 (untreated) and 3 hours after tMCAO (vehicle- or Amx-pretreated mice), and 27 hours after tMCAO (ischemic vehicle or Amx post-treated mice). (C) Quantitative analysis of HMGB1-positive microglia in the somatosensory cortex. Data are means ± S.E.M. One-way ANOVA, Dunnett’s multiple comparison tests, **P < 0.01 vs. untreated mice. (D) Following Amx treatment (10 μg/5 μl, i.c.v.) at 24 hours after 1-hour tMCAO, immunoreactive HMGB1 was still observed in the nuclei of Iba-1-positive microglia in the cortex at 48 or 96 hours after 1-hour tMCAO. Insets in (D) indicate higher magnification view of HMGB1 expression in microglia noted by dotted squares; n = 3 in each group.

Fig. 6. Amlexanox pretreatment exacerbates the ischemia-induced damage. (A and B) Following amlexanox (Amx) pretreatment (10 μg/5 μl, i.c.v.) 30 minutes before 1-hour tMCAO, TTC staining (A) and infarct volume measurement (B) were performed at 24 hours after tMCAO. Data are means ± S.E.M. Student’s t test (not significant); n = 3 in each group. (C–E) Mice were pretreated with Amx (10 μg/5 μl, i.c.v.) 30 minutes before 15-minute tMCAO. Nonischemic (NI) mice also received Amx (10 μg/5 μl, i.c.v.). TTC staining (C), infarct volume measurement (D), and clinical score (E) were performed at 24 hours after tMCAO. Data are means ± S.E.M. *P < 0.05 vs. ischemic vehicle. Untreated, n = 3; ischemic vehicle, n = 6; Amx + tMCAO, n = 6; Amx + nonischemic (NI), n = 3.
Sun et al., 2014). A previous study reported that HMGB1 is absent in microglia in the normal mouse brain, whereas brain microglia express HMGB1 following seizure (Maroso et al., 2010). Consistent with this, we observed the absence of immunoreactive HMGB1 in microglia in the normal mouse brain. By contrast, HMGB1 expression appeared in microglia as early as 3 hours after cerebral ischemia, but no HMGB1 was released from microglia in this early phase of cerebral ischemia. These findings...

Fig. 7. Late treatment with amlexanox protects the brain from ischemic damage. (A and B) Following amlexanox (Amx) post-treatment (10 μg/5 μl, i.c.v.) at 24 hours after 30-minute tMCAO, TTC staining (A) and infarct volume measurement (B) were performed at 48 hours after ischemia. Data are means ± S.E.M. Student's t test, *P < 0.05 vs. ischemic vehicle; n = 3 in each group. (C) Following Amx post-treatment at 24 hours after 30-minute tMCAO, evaluation of clinical score was performed every day for 7 days after tMCAO. Data are means ± S.E.M. *P < 0.05 vs. ischemic vehicle; n = 6 in each group. (D–F) Following Amx post-treatment (10 μg/5 μl, i.c.v.) at 48 hours after 30-minute tMCAO, TTC staining (D), infarct volume measurement (E), and clinical score evaluation (F) were performed at 72 hours after tMCAO. Data are means ± S.E.M. Student's t test, *P < 0.05 vs. ischemic vehicle; *P < 0.05 vs. ischemic vehicle; n = 4 in each group.

Fig. 8. Late treatment with anti-HMGB1 antibody inhibits ischemia-induced brain damage. (A and B) Following treatment with anti-HMGB1 antibody (α-HMGB1) at a dose of 1 or 3 μg/5 μl (i.c.v.) at 24 hours after 30-minute tMCAO, TTC staining (A) and infarct volume measurement (B) were performed at 48 hours after tMCAO. Data are means ± S.E.M. *P < 0.05 vs. ischemic vehicle; n = 3 in each group. (C and D) Following α-HMGB1 treatment (3 μg/5 μl, i.c.v.) at 24 hours after lethal cerebral ischemia (1-hour tMCAO), TTC staining (C) and infarct volume measurement (D) were performed at 48 hours after 1-hour tMCAO. Data are means ± S.E.M. *P < 0.05 vs. ischemic vehicle. n = 3 in each group. (E) Following α-HMGB1 treatment (3 μg/5 μl, i.c.v.) at 24 hours after 1-hour tMCAO, clinical score was assayed every day for 7 days after tMCAO. Data are means ± S.E.M. *P < 0.05 vs. ischemic vehicle; ischemic vehicle, n = 5; α-HMGB1 + tMCAO, n = 6.
suggest that neurons are more sensitive to ischemia than astrocytes or microglia in terms of HMGB1 release in the early phase of cerebral ischemia. HMGB1, on the other hand, was released from astrocytes but not neurons at 27 hours after tMCAO. It is still unclear why astrocytes are more sensitive to ischemia than neurons in terms of HMGB1 release in the late-ischemic phase.

On the other hand, cerebral ischemia-induced HMGB1 release from astrocytes was reversibly blocked by late treatment (24 hours after tMCAO) with amlexanox, without any effect on immunoreactive HMGB1 in neurons and microglia. On the basis of these results, we attempted to evaluate the effect of amlexanox post-treatment against ischemia-induced brain damage. Our findings suggested that late treatment with amlexanox at 24 hours, but not at 48 hours after ischemia (30-minute tMCAO) significantly inhibited ischemia-induced brain damage in terms of TTC, motor dysfunction, and lethality. Amlexanox-induced (late treatment) protection of ischemic brain was confirmed by the late treatment (i.e.,C) with neutralizing anti-HMGB1 antibody at 24 hours after 30-minute or 1 hour tMCAO, in which ischemic brain damage was significantly ameliorated by the late treatment with anti-HMGB1 antibody. Moreover, our finding with the anti-HMGB1 antibody experiment is consistent with previous studies in brain ischemia (Kim et al., 2006; Liu et al., 2007; Muhammad et al., 2008). Thus, late release of HMGB1 particularly from astrocytes contributes to ischemic brain damage. Pretreatment with amlexanox 30 minutes before tMCAO reversibly blocked cerebral ischemia-induced HMGB1 release from brain neurons at 3 hours after tMCAO, without any effect on immunoreactive HMGB1 in nuclei of astrocytes and microglia. On the basis of these findings, we observed that ischemia-induced brain damage was significantly worse at 24 hours after the ischemic stress in amlexanox-pretreated mice, as shown by TTC staining and behavioral experiments.

Recently, we demonstrated that ProTα, a signal peptideless nuclear protein, was nonclassically released from the nuclei of cultured C6 astroglialoma cells through interaction with cargo molecule S100A13 following ischemia, and this extracellular release of ProTα was reversibly blocked by amlexanox (Matsunaga and Ueda, 2010; Ueda et al., 2012). Most recently, we also reported that ProTα was nonclassically released from the nuclei of neurons as early as 3 hours after cerebral ischemia (1-hour tMCAO) and this ProTα release is reversibly blocked by the pretreatment with amlexanox (Halder et al., 2012). On the other hand, microglia did not release ProTα in the presence of cerebral ischemia, owing to absence of S100A13 expression in this glial cell (Halder et al., 2012). Taken together, it is interesting to speculate that the initiation of ischemia-induced mechanism for HMGB1 release from neurons is less important than that of the release of neuroprotective molecules such as ProTα in the early phase of cerebral ischemia. Furthermore, HMGB1, which was released from astrocytes in the late-ischemic phase, may cause the deterioration of ischemic brain damage by induction of cytotoxic cascades. Since ProTα, a neuroprotective DAMPs, is expressed in neurons and astrocytes on day 1 (27 hours) after cerebral ischemia independently of amlexanox (Halder et al., 2012), the blockade of HMGB1 release from astrocytes either by amlexanox or anti-HMGB1 antibody late treatment may be a novel approach to protection against ischemic brain damage.

Further studies would be necessary to examine the effects of amlexanox on HMGB1 level in the CSF under cerebral ischemia, the effects of amlexanox late treatment on brain HMGB1 levels at later time points, and whether the gene silencing of amlexanox targets such as S100A13 mimics the amlexanox effects. In addition, it would also be interesting to see how pretreatment with anti-HMGB1 antibody affects ischemia-induced brain damage, since the neuroprotective DAMP molecule ProTα is also released upon ischemic stress in an amlexanox-reversible manner (Halder et al., 2012). As many other DAMPs molecules would also be released upon acute ischemic stress, detailed analysis of the contribution of released HMGB1 needs more extensive analysis, including the effects of gene silencing of HMGB1.

Amlexanox reversibly blocked ischemia-induced early release of HMGB1 from neurons and late release from astrocytes, but we do not know how HMGB1 release is inhibited by amlexanox. As there are reports that amlexanox has multiple pharmacological actions (Bell, 2005; Zhang et al., 2015), the molecular-based mechanisms underlying ischemia-induced nonclassical release of HMGB1 may not be simple. However, as amlexanox inhibits the nonclassical release of various DAMPs molecules, including IL-1α, fibroblast growth factor (FGF)-1 and ProTα (Prudovsky et al., 2003, 2008; Matsunaga and Ueda, 2008, 2010), which commonly use S100A13 as a cargo protein, the study of interaction between HMGB1 and S100A13 represents an obvious approach to clarify the mechanisms underlying HMGB1 release.

In conclusion, pretreatment with amlexanox blocked cerebral ischemia-induced early release of HMGB1 from neurons but failed to protect the brain from ischemic damage. Late treatment with amlexanox blocked HMGB1 release from astrocytes 27 hours after ischemia and subsequently limited the extent of ischemic brain damage. In addition, ischemia-induced brain damage was ameliorated by late treatment with the anti-HMGB1 antibody. Although amlexanox is clinically used as a safe anti-allergy medicine, this compound has multiple cellular targets in the periphery of the body. Therefore, the present discovery of pharmacological regulation of delayed and harmful HMGB1 release may provide a new strategy for developing antistroke medicines that possess a wide therapeutic time frame.

Acknowledgments

The authors thank Dr. H. Matsunaga, Dr. Y. Matsushita, H. Yamaguchi, and J. Sugimoto for technical help and acknowledge Takeda Pharmaceutical Company Ltd. for providing amlexanox. The authors also thank Dr. R. Milner (Associate Professor, The Scripps Research Institute, La Jolla) for checking the English grammar throughout the manuscript.

Authorship Contributions

Participated in research design: Ueda, Halder.
Conducted experiments: Halder.
Performed data analysis: Halder.
Contributed new reagents or analytic tools: Ueda.
Wrote or contributed to the writing of the manuscript: Ueda, Halder.

References
